| 1. | | Recruiting | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm |
| 2. | | Recruiting | 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer |
| 3. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: Cancer |
| 4. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma |
| 5. | | Recruiting | 17-DMAG to Treat Patients with Solid Tumors or Lymphomas
Conditions: Neoplasms; Lymphoma |
| 6. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Condition: Cancer |
| 7. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Conditions: adult Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; adult non-Hodgkin's lymphoma; adult solid tumor; Cutaneous T-Cell Lymphoma; ... |
| 8. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Conditions: Ewing's family of tumors; childhood rhabdomyosarcoma; childhood soft tissue sarcoma; hematopoietic and lymphoid cancer; Neuroblastoma; Osteosarcoma |
| 9. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: unspecified childhood solid tumor, protocol specific; recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia; ... |
| 10. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
| 11. | | Recruiting | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Chronic Myelogenous Leukemia; secondary acute myeloid leukemia |
| 12. | | Recruiting | 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: acute leukemia; adult acute monoblastic and acute monocytic leukemia; atypical chronic myeloid leukemia; chronic leukemia; ... |
| 13. | | Recruiting | 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: recurrent adult acute lymphoblastic leukemia; T-cell adult acute lymphoblastic leukemia; recurrent adult lymphoblastic lymphoma |
| 14. | | Recruiting | Activation and Function of Eosinophils in Conditions with Blood or Tissue Eosinophilia
Conditions: Asthma; Eosinophilia; Helminthiasis; Hypersensitivity; Parasitic Disease |
| 15. | | Recruiting | Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
Conditions: Cancer; oral complications of cancer and cancer therapy; Pain |
| 16. | | Recruiting | Acute Myeloid Leukemia Study
Condition: Acute Myeloid Leukemia |
| 17. | | Recruiting | Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Conditions: stage II multiple myeloma; stage III multiple myeloma |
| 18. | | Not yet recruiting | Adoptive Immunotherapy and Interleukin-2 in Treating Patients With Recurrent Accelerated or Blast Phase Chronic Myelogenous Leukemia After Undergoing Allogeneic Stem Cell Transplantation
Conditions: accelerated phase chronic myelogenous leukemia; blastic phase chronic myelogenous leukemia; relapsing chronic myelogenous leukemia; ... |
| 19. | | Recruiting | AG-858 and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Were Previously Treated With Imatinib Mesylate
Conditions: chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia |
| 20. | | Recruiting | AG-858 in Patients who are Cytogenetically Positive after Treatment with Gleevec™
Condition: Leukemia, Myeloid, Chronic |
| 21. | | Recruiting | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Conditions: B-cell adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; L2 adult acute lymphoblastic leukemia; ... |
| 22. | | Recruiting | Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
Conditions: Cutaneous T-Cell Lymphoma; mycosis fungoides and Sezary syndrome |
| 23. | | Recruiting | Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia |
| 24. | | Not yet recruiting | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease; Non-Hodgkin's Lymphoma; ... |
| 25. | | Recruiting | Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Conditions: stage III chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia; ... |
| 26. | | Recruiting | Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
Condition: recurrent childhood acute lymphoblastic leukemia |
| 27. | | Recruiting | Alemtuzumab, Total-Body Irradiation, and Fludarabine Followed By Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; hematopoietic and lymphoid cancer |
| 28. | | Recruiting | Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia |
| 29. | | Recruiting | Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
Condition: recurrent adult Hodgkin's lymphoma |
| 30. | | Recruiting | Angiomax in Patients with HIT/HITTS Type II Undergoing CPB
Conditions: Cardiovascular Disease; Coronary Artery Bypass Surgery |
| 31. | | Recruiting | Angiomax in Patients with HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
Conditions: Thrombocytopenia; Thrombosis; Cardiac Disease; Coronary Artery Bypass Surgery |
| 32. | | Recruiting | Anidulafungin in Treating Immunocompromised Children With Neutropenia
Conditions: Infection; Neutropenia; unspecified childhood solid tumor, protocol specific |
| 33. | | Recruiting | Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection; T Cell Leukemia |
| 34. | | Recruiting | Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Conditions: Leukemia; Lymphocytic; Chronic |
| 35. | | Recruiting | Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Conditions: Lymphoma; T-Cell; Cutaneous |
| 36. | | Recruiting | Anti-Thymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplantation for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Graft Versus Host Disease; secondary acute myeloid leukemia |
| 37. | | Recruiting | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Conditions: stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; Infection |
| 38. | | Recruiting | Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Conditions: grade 1 follicular lymphoma; grade 2 follicular lymphoma; marginal zone lymphoma; Small Lymphocytic Lymphoma |
| 39. | | Recruiting | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Conditions: contiguous stage II mantle cell lymphoma; noncontiguous stage II mantle cell lymphoma; stage III mantle cell lymphoma; stage IV mantle cell lymphoma; ... |
| 40. | | Recruiting | Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Conditions: refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma |
| 41. | | Recruiting | Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Condition: adult non-Hodgkin's lymphoma |
| 42. | | Recruiting | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Condition: primary central nervous system lymphoma |
| 43. | | Recruiting | Antithymocyte Globulin and Cyclosporine Compared With Standard Therapy in Treating Patients With Myelodysplastic Syndrome
Conditions: Refractory Anemia; refractory anemia with ringed sideroblasts; refractory anemia with excess blasts; de novo myelodysplastic syndromes; ... |
| 44. | | Recruiting | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: refractory chronic lymphocytic leukemia; noncontiguous stage II small lymphocytic lymphoma; recurrent small lymphocytic lymphoma; ... |
| 45. | | Recruiting | Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
Conditions: Anemia, Sickle Cell; Pneumonia |
| 46. | | Recruiting | Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Conditions: de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes; ... |
| 47. | | Recruiting | Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Conditions: accelerated phase chronic myelogenous leukemia; blastic phase chronic myelogenous leukemia; recurrent adult acute lymphoblastic leukemia; ... |
| 48. | | Recruiting | Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: chronic phase chronic myelogenous leukemia; Philadelphia chromosome positive chronic myelogenous leukemia |
| 49. | | Recruiting | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Conditions: adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; indolent or aggressive adult non-Hodgkin's lymphoma; Prolymphocytic Leukemia; ... |
| 50. | | Recruiting | Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
Condition: refractory plasma cell neoplasm |
